Cingulate therapeutics filing

Author: htng

August undefined, 2024

WebMar 10, 2024 · Inside Cingulate Inc.'s 10-K Annual Report: Financial - Expense Highlight. We have experienced, and will continue to experience, increased expenses associated … WebCingulate Inc. Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation ...

SEC FORM D/A

WebSep 24, 2014 · Somerset, N.J. – September 24, 2014 — Catalent Pharma Solutions has reached an exclusive development and licensing agreement with privately held biopharmaceutical company, Cingulate Therapeutics (CTx), to support the development of a series of new prescription pharmaceutical products for the treatment of Attention … WebMar 30, 2024 · (a) the Company’s latest annual report on Form 10-K filed pursuant to Section 13(a) or 15(d) of the Exchange Act for the fiscal year ended December 31, 2024, as filed with the Commission on ... psat test breakdown

Cingulate Therapeutics LLC - DE, KS, and TX - Bizapedia

WebJul 3, 2024 · Cingulate Therapeutics - ‘D/A’ on 7/3/19 - Notice of an Exempt Offering of Securities - Seq. 1 - Amendment to Notice of an Exempt Offering of Securities -- primary_doc.xml/7.8 - Accession Number 0001593151-19-000001 - Filing - SEC WebCingulate General Information. Description. Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery … WebAbout Cingulate®. Cingulate® (CTx®)is a Phase 3 clinical stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build and advance a pipeline of branded next-generation pharmaceutical products.These will be designed to improve the lives of patients suffering from frequently diagnosed … horse racing with cards

Cingulate Company Profile: Stock Performance & Earnings

WebSep 14, 2024 · Cingulate, Inc. ( NASDAQ: CING) is a clinical-stage biopharmaceutical company with a proprietary Precision Timed Release (PTR) drug delivery platform … WebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate Therapeutics: Street Address 1 Street Address 2; 6 SOUTH STREET: SUITE 203: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; MORRISTOWN: NEW … psat test 10 answersWebFeb 8, 2024 · Cingulate Therapeutics LLC. February 8, 2024, ... (U.S.) and are instrumental for the filing of the New Drug Application to the U.S. Food and Drug Administration (FDA), expected in the second half ... horse racing with a cart

"WebApr 2, 2024 · About Cingulate Therapeutics. ... Cingulate anticipates filing INDs for both assets in the third and fourth quarters of 2024 and will pursue approval via the accelerated 505(b)(2) regulatory ... " - Cingulate therapeutics filing

Cingulate therapeutics filing

CING Institutional Ownership and Shareholders - Cingulate Inc …

WebCingulate Therapeutics is a Biotechnology, Pharmaceuticals, and Pharmaceutical Manufacturing company located in Morristown, New Jersey with $2.00 Million in revenue and 14 employees. Find top employees, contact details and business statistics at RocketReach. ... (28 currently) – along with the filing of multiple provisional applications ... WebSep 9, 2024 · Cingulate Inc. S-1 Filing information. Filed on 9 September 2024 SEC Edgar 000149315221022284 Exhibits & attachments & exports. ... Top menu > File > Make a …

Did you know?

WebApr 6, 2024 · Cingulate's stock was trading at $1.00 at the beginning of the year. Since then, CING stock has decreased by 3.8% and is now trading at $0.9619. View the best growth stocks for 2024 here. WebUncategorized (1) Contracts. Master Services Agreement between Cingulate Therapeutics LLC and Societal CDMO, Inc., dated October 24, 2024 (Filed With SEC on October 25, 2024) Promissory Note, dated August 9, 2024, between Cingulate Therapeutics, LLC and Werth Family Investment Associates LLC (Filed With SEC on August 11, 2024) …

WebJul 10, 2024 · About Cingulate Therapeutics. ... Cingulate anticipates filing INDs for both products in the first quarter of 2024 and will pursue approval via the accelerated 505 (b)(2) regulatory pathway. ... WebCINGULATE THERAPEUTICS LLC. CINGULATE INC. AND. CINGULATE PHARMA LLC. DATED AS OF AUGUST 30, 2024 . ... 2024, which in turn formed Merger Sub by filing …

WebCingulate Therapeutics is based out of Morristown. The firm last filed a Form D notice of exempt offering of securities on 2024-06-29. The notice included securities offered of … WebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate …

WebCingulate Therapeutics uses a unique combination of delivery technology and proven medications that creates an unmatched release profile. … horse racing wizardWebMay 31, 2024 · Cingulate anticipates filing INDs for CTX-1301 and CTX-1302 via the accelerated 505 (b)(2) regulatory pathway. The company has offices in Kansas City, KS and Morristown, NJ. For more information ... horse racing with buggiesWebJun 29, 2024 · The most recently filed 13Fs psat test for homeschoolersWebJul 11, 2024 · About Cingulate Therapeutics ... Cingulate anticipates filing INDs for both assets in the third and fourth quarters of 2024 and will pursue approval via the accelerated 505(b)(2) regulatory ... psat test ivy string answer keyWebApr 11, 2024 · On April 04, 2024, Cingulate Inc. (NASDAQ: CING) announced it had completed the first cohort of its Phase 3 adult onset and duration trial of its lead candidate, CTx-1301 (dexmethylphenidate), for attention deficit/hyperactivity disorder (ADHD). The Phase 3 CTx-1301-022 study (NCT05631626) assesses the onset and duration of CTx … horse racing with buggyWebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate Therapeutics: Street Address 1 Street Address 2; 6 SOUTH STREET: SUITE 203: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; MORRISTOWN: NEW … psat test bookWebMar 31, 2024 · The transplantation of neural progenitors into a host brain represents a useful tool to evaluate the involvement of cell-autonomous processes and host local cues in the regulation of neuronal differentiation during the development of the mammalian brain. Human brain development starts at the embryonic stages, in utero, with unique … horse racing with music